An open-label, multicenter, ascending dose study of the tolerability and safety of recombinant human acid sphingomyelinase (rhASM) in patients with ASM deficiency (ASMD)

Authors :: Melissa P. Wasserstein
Brenda Pimlott
Kerry Culm-Merdek
Beth L. Thurberg
Handrean Soran
Andrew Cunningham
Natalie Lippa
Catherine Breen
Simon Jones
Source :: Molecular Genetics and Metabolism. 111:S57
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: business.industry
Endocrinology, Diabetes and Metabolism
Pharmacology
Biochemistry
law.invention
Endocrinology
Tolerability
law
Genetics
medicine
Recombinant DNA
In patient
Open label
Acid sphingomyelinase
business
Molecular Biology
medicine.drug

Tools